1. J.A. Montgomery, Experimental studies at Southern Research Institute with DTIC (NSC45388), Cancer Treat. Rep. 60: 125 (1976).
2. D.H. Cowan, and D.E. Bergsagel, Intermittent treatment of metastatic malignant melanoma with high dose 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC45388), Cancer Chemoter. Rep. 55: 175 (1971).
3. K.I. Pritchard, I.C. Quirt, D.H. Cowan, D. Osoba and, G.J. Kutas, DTIC therapy in metastatic malignant melanoma: a simplified dose schedule, Cancer Treat. Rep. 64: 1123 (1980).
4. G.J. Hill, G.E. Metter, S.E. Moss, and F.M. Golomb, DTIC therapy for melanoma: correlation of toxicity with response and longevity in 742 patients, AACR Proc. 17: 244 (1976).
5. G.J. Hill, S.E. Moss, F.M. Golomb, and G.E. Metter, DTIC and combination therapy for melanoma, Cancer 47: 25 (1981).